The relevance of pharmacokinetics to monitoring new antiarrhythmics.
The application of selective and sensitive methodology to the investigation of the pharmacokinetics of new antiarrthythmic drugs is described. The value of these data in the context of routine measurements as a guide to therapy is discussed. In particular, specific case histories that demonstrate the considerable within- and between-subject variation in pharmacokinetic parameters are cited and used to illustrate the potential benefits of drug monitoring. We conclude that studies designed to elucidate the pharmacokinetics of these drugs in a variety of clinical settings can be a valuable guide to assessing the patient groups for whom routine monitoring would be of particular benefit when the drugs are in general clinical use.